Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Federico Stella, MD, on the controversial practice of severely restricting the diets of patients who have just undergone stem cell transplants. Read the full story here: Italian Hematologist Urges End to ‘Useless’ Restrictive Diets After Stem Cell Transplants
The routine measurement of bone remodeling biomarkers should be performed in all patients with systemic mastocytosis (SM), according to findings from a cross-sectional study published in The Journal of Allergy and Clinical Immunology: In Practice. In patients with SM, tissue accumulation of clonal mast cells often includes bone involvement. Although several mast cell mediators, such…
Significant disease progression during a 24-month period has been detected in 18% of patients with indolent systemic mastocytosis (SM) and up to a third of patients with indolent SM may experience high symptom burden, according to an abstract published in a special issue of the Journal of Allergy and Clinical Immunology. The study was presented…
CCL23 (chemokine ligand 23) has been suggested as a biomarker for systemic mastocytosis (SM), with CCL23 plasma cells associated with disease severity, according to findings from a study published in The Journal of Allergy and Clinical Immunology. SM has been described as a heterogeneous group of disorders in which accumulation of neoplastic mast cells in…
Avapritinib (Ayvakit®) plus best supportive care improved symptoms and quality of life (QoL) in patients with indolent systemic mastocytosis (SM), according to results from the registrational PIONEER trial. The findings will be presented in a poster at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting being held February 24 to 27, 2023, in…
A diagnosis of systemic mastocytosis (SM) was delayed for 6 years in a patient who suffered from unexplainable skin rashes, according to a case report published in Case Reports in Oncology. The authors detailed the case of a 40-year-old male patient with chronic itchy skin lesions. The rash, which initially appeared 6 years prior, would…
Results from the registrational PIONEER trial suggest that avapritinib (Ayvakit®) improves skin signs and symptoms in patients with indolent systemic mastocytosis (SM). The results will be presented in a late-breaking presentation at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting being held February 24-27 in San Antonio, Texas. “Avapritinib-treated patients experienced…
Individuals with nonadvanced systemic mastocytosis (SM) experience a myriad of severe, debilitating symptoms that can impact their health-related quality of life (HRQoL), according to findings from 90-minute qualitative virtual interviews conducted among US adult patients with the disease. Results of the study will be presented at the 2023 American Academy of Allergy, Asthma & Immunology…
The case presentation of a female patient with systemic mastocytosis (SM) who suffered a life-threatening anaphylactic reaction during cardiac surgery, as well as a systematic review of the related literature, was recently published in the Journal of Clinical Medicine. The authors reported on the case of a 66-year-old woman admitted for planned aortic valve replacement.…
A postmarketing pharmacovigilance analysis of avapritinib, a medication used in the treatment of systemic mastocytosis (SM), discovered that elderly male patients were at an increased risk of experiencing serious adverse events related to treatment. The study was published in the British Journal of Clinical Pharmacology. The study authors extracted 3120 avapritinib-related reports submitted to the US…
Please login or register first to view this content.
